Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Rhythm · Phase 3 · Completed · Enrollment 19

NCT05194124

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Run-in Period: Setmelanotide 2 mg QD0 participants0 participants0 participantsn/r0
Run-in Period: Setmelanotide 2.5 mg QD0 participants0 participants0 participantsn/r0
Run-in Period: Setmelanotide 3 mg QD0 participants0 participants0 participantsn/r0
DB Period: Setmelanotide 20 mg QW0 participants0 participants0 participantsn/r0
DB Period: Setmelanotide 25 mg QW1 participants0 participants0 participantsn/r0
DB Period: Setmelanotide 3 mg QD3 participants2 participants2 participantsn/r0
DB Period: Setmelanotide 30 mg QW0 participants0 participants0 participantsn/r0
OL Period: Setmelanotide 20 mg QW0 participants0 participants0 participantsn/r0
OL Period: Setmelanotide 25 mg QW1 participants0 participants0 participantsn/r0
OL Period: Setmelanotide 30 mg QW0 participants1 participants2 participantsn/r0

A count stays a count. This page does not turn a count into a percent.